Abstract
The effectiveness of l-α-lysophosphatidylcholine (LPC) as an enhancer for the nasal delivery of large peptide drugs was investigated in rats using insulin as a model drug. Intranasal insulin (16.7 IU/kg) solutions in combination with 0.5% of this enhancer produced a 65% decrease in blood glucose levels, which was similar to the decrease obtained using laureth-9 as a known enhancer. The two main constituents of LPC, namely, the palmitoyl component (72%) and the stearoyl component (24%) produced similar effects, at a concentration of 0.5%, to that of LPC, thus indicating that both of these lysophospholipids are equally potent absorption enhancers with potential in nasal delivery.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
